These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 30316578

  • 1. What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
    Sun G, Zhang X, Chen J, Liao B, Liu Z, Zhao J, Gao AC, Yang Y, Shu K, Liu J, Zhao P, Shen P, Zeng H.
    Urol Oncol; 2018 Dec; 36(12):505-517. PubMed ID: 30316578
    [Abstract] [Full Text] [Related]

  • 2. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 3. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
    Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Nomura K, Habuchi T.
    World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [Abstract] [Full Text] [Related]

  • 5. Real-world outcomes and risk stratification in patients with metastatic castration-sensitive prostate cancer treated with upfront abiraterone acetate and docetaxel.
    Narita S, Kimura T, Hatakeyama S, Hata K, Yanagisawa T, Maita S, Chiba S, Sato H, Kashima S, Koizumi A, Yamamoto R, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Suzuki T, Ohyama C, Egawa S, Habuchi T.
    Int J Clin Oncol; 2022 Sep; 27(9):1477-1486. PubMed ID: 35748967
    [Abstract] [Full Text] [Related]

  • 6. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L, Shohdy KS, Abdel-Rahman O.
    Curr Med Res Opin; 2018 May; 34(5):903-910. PubMed ID: 29490505
    [Abstract] [Full Text] [Related]

  • 7. Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
    Yanagisawa T, Hata K, Narita S, Hatakeyama S, Mori K, Yata Y, Sano T, Otsuka T, Hara S, Miyajima K, Enei Y, Fukuokaya W, Nakazono M, Matsukawa A, Miki J, Habuchi T, Ohyama C, Shariat SF, Kimura T.
    Prostate; 2023 May; 83(6):563-571. PubMed ID: 36661102
    [Abstract] [Full Text] [Related]

  • 8. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z, Saad F, Fizazi K.
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
    Wang Y, Zhang H, Shen W, He P, Zhou Z.
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.
    Wang T, Wang X, Ding G, Liu H, Ma X, Ma J, Cui Y, Wu J.
    Br J Cancer; 2024 Nov; 131(8):1363-1377. PubMed ID: 39223303
    [Abstract] [Full Text] [Related]

  • 11. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S.
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [Abstract] [Full Text] [Related]

  • 12. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [Abstract] [Full Text] [Related]

  • 13. Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
    Smith KER, Brown JT, Wan L, Liu Y, Russler G, Yantorni L, Caulfield S, Lafollette J, Moore M, Kucuk O, Carthon B, Nazha B, Bilen MA.
    Oncologist; 2021 Nov; 26(11):956-964. PubMed ID: 34096667
    [Abstract] [Full Text] [Related]

  • 14. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, De Porre P, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K.
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P, Manka L.
    Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis.
    Chen J, Ni Y, Sun G, Liao B, Zhang X, Zhao J, Zhu S, Wang Z, Shen P, Zeng H.
    Front Oncol; 2020 Oct; 10():519388. PubMed ID: 33072564
    [Abstract] [Full Text] [Related]

  • 18. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T, Fukuokaya W, Shim SR, Mostafaei H, Motlagh RS, Quhal F, Laukhtina E, Pallauf M, Pradere B, Kimura T, Egawa S, Shariat SF.
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [Abstract] [Full Text] [Related]

  • 19. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
    Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, Shariat SF, Sevcenco S, Maj-Hes A, Kramer G.
    Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.